I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Source: SeekingAlpha
2025-08-11 12:44:59 ET
Thesis
My research argues that Haemonetics Corporation (NYSE: HAE ) remains a high-quality blood-management franchise, anchored by TEG hemostasis, advanced plasma platforms, and vascular closure devices, with durable, high-margin economics and a strong U.S. base plus underpenetrated international upside. That said, Q1 FY2026 highlights a pause in the broader growth story: recent changes to its product lineup, tougher competition in some parts of the business, and growth that was boosted by one-time factors have slowed momentum, even though profits and cash flow remain healthy....
Read the full article on Seeking Alpha
For further details see:
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Haemonetics Corporation
NASDAQ: HAE
HAE Trading
-2.31% G/L:
$54.65 Last:
1,028,685 Volume:
$55.28 Open:
HAE Latest News
March 20, 2026 06:03:10 pm
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
February 23, 2026 04:15:00 pm
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
February 20, 2026 04:05:00 pm
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
HAE Stock Data
$2,748,315,639
45,616,277
0.08%
124
N/A
Medical Equipment & Supplies
Healthcare
US
Boston
